Nov 10, 2021
- Received Fast Track Designation for REC-2282, a potential treatment for NF2 meningiomas, and expect to enroll the first patient in a Phase 2/3 trial in early 2022 - Advanced REC-994, a potential treatment for CCM, and now expect to enroll the first patient in a phase 2 trial in early 2022 -
Aug 16, 2021
Christensen to lead Recursion's Toronto office, opening in 2021 SALT LAKE CITY, Aug. 16, 2021 / PRNewswire / -- Recursion, a digital biology company industrializing drug discovery, today announced the appointment of Jordan Christensen as its Vice President of Engineering.
Aug 13, 2021
- Expanded the total number of research and development programs from 37 to 48 - Announced first internally-developed NCE is advancing to IND-enabling studies - Planning to expand operations to Canada, with Toronto serving as a multidisciplinary hub - Formed Therapeutics Advisory Board chaired by
Jul 12, 2021
Recursion and Bright Horizons partner to open child care center in Gateway Mall, next to Recursion's Salt Lake City headquarters SALT LAKE CITY , July 12, 2021 / PRNewswire / -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological
Displaying 31 - 40 of 64